WuXi Biologics, a separate company, which makes therapies from living cells, has opened facilities in King of Prussia and Cranbury, N.J., in recent years. Altaris has invested in more than 40 life ...

Altaris has “committed to growing the [Advanced Therapies Unit] by supporting its employees, customers and patients,” while his WuXi AppTec will continue in its other businesses “to move toward our ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing ...

China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...

A Merck KGaA brand logo stands in front of the company premises. WuXi Biologics, a Chinese biopharmaceuticals company, announced on 06 January the sale of its WuXi Vaccines facility in Ireland to ...

With potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a sizable ...